Kalvista Pharmaceuticals Inc (KALV) - Total Assets
Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) holds total assets worth $339.93 Million USD as of October 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See KALV stock price and chart for real-time trading data and today's change.
Kalvista Pharmaceuticals Inc - Total Assets Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see KALV cash flow conversion for how efficiently the company converts equity into cash flow.
Kalvista Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (April 2025)
Kalvista Pharmaceuticals Inc's total assets of $339.93 Million consist of 96.4% current assets and 3.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.3% |
| Accounts Receivable | $15.14 Million | 6.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Kalvista Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore KALV working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalvista Pharmaceuticals Inc's current assets represent 96.4% of total assets in 2025, a decrease from 97.6% in 2013.
- Cash Position: Cash and equivalents constituted 39.3% of total assets in 2025, down from 96.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 6.0% of total assets.
Kalvista Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Kalvista Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MAIA Biotechnology Inc.
NYSE MKT:MAIA
|
USA | $35.32 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
|
USA | $1.15 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.77 Billion |
|
Absci Corp
NASDAQ:ABSI
|
USA | $195.59 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Kalvista Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.22 | 6.87 | 9.59 |
| Quick Ratio | 7.21 | 6.87 | 9.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $280.16 Million | $130.10 Million | $55.99 Million |
Kalvista Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Kalvista Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 48.09 |
| Latest Market Cap to Assets Ratio | 3.27 |
| Asset Growth Rate (YoY) | 6.5% |
| Total Assets | $250.77 Million |
| Market Capitalization | $820.37 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Kalvista Pharmaceuticals Inc's assets at a significant premium (3.27x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Kalvista Pharmaceuticals Inc's assets grew by 6.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual total assets of Kalvista Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-04-30 | $250.77 Million | +6.53% |
| 2024-04-30 | $235.40 Million | +28.49% |
| 2023-04-30 | $183.20 Million | -10.14% |
| 2022-04-30 | $203.88 Million | -25.05% |
| 2021-04-30 | $272.01 Million | +193.98% |
| 2020-04-30 | $92.53 Million | -21.67% |
| 2019-04-30 | $118.13 Million | +92.43% |
| 2018-04-30 | $61.39 Million | +78.74% |
| 2017-04-30 | $34.34 Million | +38.80% |
| 2016-04-30 | $24.75 Million | -50.19% |
| 2016-03-31 | $49.67 Million | -12.53% |
| 2015-12-31 | $56.79 Million | +754.77% |
| 2015-04-30 | $6.64 Million | 0.00% |
| 2014-12-31 | $6.64 Million | -34.25% |
| 2014-04-30 | $10.11 Million | +18.48% |
| 2013-04-30 | $8.53 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more